Galapagos NV announced changes in the Executive Committee effective 1 January 2023. Dr. Walid Abi-Saab has decided to retire from the company as Chief Medical Officer and member of the Executive Committee, effective 31 December 2022. He will stay with Galapagos until 31 May 2023 to ensure a smooth transition. The company also announced the retirement of André Hoekema who joined Galapagos in 2005 as Chief Business
Officer and member of the Executive Committee. The company anticipates announcing a Head of R&D and Executive Committee member in the first half of 2023. Until such appointment, Dr. Paul Stoffels will act as Head of R&D ad interim. Additionally, the company's senior leadership team has been strengthened with key hires and internal promotions in Research, Development, Business Development and Commercial. Furthermore, the Board of Directors of Galapagos appointed two new members to the Executive Committee: Ms. Annelies Missotten, Chief Human Resources Officer - Annelies joined Galapagos early 2018 from GSK, where she was HR Business Leader of Global Vaccines Commercial & Global Vaccines Strategic Partnerships; Ms. Valeria Cnossen, General Counsel, also responsible for Compliance & Ethics, the Corporate Secretary Office and Intellectual Property; and Valeria joined Galapagos in August 2022. She previously was General Counsel of the Consumer Health Group of Johnson & Johnson and held leadership roles in the Pharmaceuticals Group and Medical Devices Group of Johnson & Johnson.